netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.05.05.02  Expand sub section  Angiotensin-II receptor antagonists
Candesartan
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 2mg, 4mg, 8mg, 16mg, 32mg

 
   
Irbesartan
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 75mg, 150mg, 300mg

 
   
Losartan
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 12.5mg, 25mg, 50mg, 100mg 

 
   
Sacubitril / Valsartan (Entresto)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 3

Film-coated tablets: 24mg/26mg, 49mg/51mg, 97mg/103mg

Notes:

  • This drug is for a heart failure specialist initiation and stabilisation within its licensed indication only. The specialist should have access to a multidisciplinary heart failure team.
  • Used as an option in accordance to NICE TA388 (April 2016) - see link below.
  • Sacubitril/Valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
    1. with New York Heart Association (NYHA) class II to IV symptoms and
    2. with a left ventricular ejection fraction of 35% or less and
    3. who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor-blockers (ARBs).
  • Prescriber must ensure that the patient's current treatment regime is optimal and that they are taken as agreed. Exerpts from ESC Guidelines are:
  • Therapeutic algorithm and Evidence-based doses for heart failure with reduced ejection fraction (Excerpt from ESC guidelines)
  • Full ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (May 2016)
  • Dose titration and monitoring should be performed by the most appropriate team member as defined in NICE's guideline on chronic heart failure in adults: management (September 2018).
 
Link  NICE TA388: Sacubitril valsartan for heart failure
Link  SMC advice (March 2016)
   
Valsartan
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 40mg, 80mg, 160mg, 320mg

 
   
 ....
 Non Formulary Items
Azilsartan
(Edarbi)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cozaar- Comp
(Losartan & hydrochlorothiazide)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Eprosartan  (Teveten)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Olmesartan  (Sevikar)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Telmisartan

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary